ROCHESTER, N.Y., Jan. 25, 2012 (GLOBE NEWSWIRE) — NaturalNano, Inc. (OTCBB:NNAN) (www.naturalnano.com) announced today that Dr. Michael King of Cornell University will present at the CTC, Circulating Tumor Cell, Conference in San Diego, California on February 2 at 11:45 am (PST). (http://selectbiosciences.com ). Dr. King’s presentation reports his recent work showing how thin coatings of naturally-forming Halloysite nanotubes can greatly improve the efficiency of CTC capture from blood samples under flow.
Dr. King, an Associate Professor of biomedical engineering at Cornell University, states “The capture of circulating tumor cells (CTCs) in blood can be targeted more effectively by incorporation of Halloysite nanotubes (HNT) onto the surface of FLOW devices used to capture CTCs in blood.” King continued, “The flow devices with HNT incorporated onto their surface were found to significantly enhance the naturally occurring CTC rolling mechanism. This allows those cells to be exposed to specific therapeutic agents or isolated and collected for diagnostic and research purposes.”
James Wemett, NaturalNano CEO, said “We are pleased to have our HNT technology used in Dr. King’s important work. Wemett continued, “Dr. King’s work with HNT continues to build on our understanding of the potential role that HNT may play in Life Science applications. The use of HNT showed no harmful effect on cells, enabling greater efficiency in the capture of live cells ready for treatment or analysis.”
About NaturalNano, Inc.
NaturalNano, Inc. (OTCBB:NNAN) is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives. www.naturalnano.com
Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano’s filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.
CONTACT: Jim Wemett email@example.com NaturalNano, Inc. 585-267-4848